ROCO
4728
Market cap675mUSD
Oct 08, Last price
396.00TWD
1D
0.38%
1Q
5.04%
Jan 2017
838.39%
IPO
1,100.00%
Name
Sunmax Biotechnology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across Taiwan and mainland China. Its diverse product line encompasses Porcogen, a sterile, purified collagen solution valuable for medical device applications, tissue engineering, and research. Sunmax also supplies various dermal fillers, including the Sunmax collagen implant series (I-Plus, I) and FACIALGAIN collagen implants (with and without lidocaine), engineered for correcting facial aesthetic concerns such as wrinkles. For dental procedures, they provide specialized collagen-based solutions like Sunmax collagen dental bone grafts, membranes, and granules, used for augmenting or reconstructing the alveolar ridge, extraction sockets, and in periodontics. Additionally, the Sunmax collagen bone graft matrix serves as a bone void filler that naturally resorbs and facilitates new bone formation during recovery. The company's offerings extend to skincare products, such as Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and a general collagen skincare line, all designed for post-dermal filler treatment aftercare.
Key people
Mingyi Lin
General Manager · since 2023
Chun Chiang Chang
Deputy General Manager-Administration · since 2022
Yude Lin
Deputy General Manager-Technology Division · since 2002
Guangheng Lin
Executive Deputy General Manager · since 2019
Jiazhen Cai
Corporate Governance Officer · since 2023
Shixing Zhuang
Head of Finance & Accounting · since 2022
Director · since 2023
Fangying Chen
Director · since 2022
Director · since 2025
Yuehan Jiang
Director · since 2025
Yuxuan Lin
Director · since 2022
Jinhan Lin
Director · since 2025
Jingxuan Lin
Director · since 2025
Qiguo Lin
Chairman of the Board, Chief Executive Officer · since 2022
Xiejian Lin
Director · since 2025
Jingwen Su
Director · since 2021
Yanji Yang
Vice Chairman of the Board · since 2022
Kangrong Zhan
Director · since 2022
Guohua Chen
Independent Director · since 2019
Jingjia Shen
Independent Director · since 2022
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||